Arena Pharma (ARNA) Posts Narrower than Expected Q4 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
- S&P 500, Nasdaq end lower as crude prices jump, chip stocks weigh
- Oil rises 4% on revived Middle East worries, Hurricane Isaias supply disruption
- Chipotle, Starbucks shares volatile after report of potential takeover
- Why Citi says the Fed could be setting up for a dovish surprise
- Alphabet shares rise as Google pushes Gemini deeper into enterprise AI
Tweet
Share
E-mailGet Alerts ARNA Hot Sheet
Price: $99.98 --0%
Financial Fact:
Research and development: 17.47M
Today's EPS Names:
PKE, BYRN, HELE, More
Financial Fact:
Research and development: 17.47M
Today's EPS Names:
PKE, BYRN, HELE, More
Join SI Premium – FREE
Arena Pharmaceuticals (NASDAQ: ARNA) reported Q4 loss of $0.23, $0.02 worse than the analyst estimate of ($0.21). Revenue for the quarter came in at $4.01 million versus the consensus estimate of $4.81 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Helen of Troy (HELE) Tops Q2 EPS by 28c, Misses on Revenue; Offers FY27 Guidance
- Neogen Corp. (NEOG) Tops Q1 EPS by 3c
- Novagold Resources, Inc. (NG) Misses Q3 EPS by 2c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
